#1
JOURNAL ARTICLE
Peter Nielsen, Rosemarie Kongi, Peter Buggisch, Roland Fischer
The bioavailability of the oral iron compound iron(II)-glycine sulfate (ferro sanol duodenal, FSD, 1 x 100 mg Fe/d) was studied in 56 patients with iron deficiency anaemia using a 59Fe-labelling technique and 59Fe-whole-body counting. This technique measures the individual iron loss and allows in patients with substantial blood loss under iron medication a reliable information on the bioavailability of the drug. In all patients, the increased loss of iron (mean 5.8 +/- 4.4 mg/d) was clearly compensated by the iron utilisation (mean: 11...
2005: Arzneimittel-Forschung
#2
RANDOMIZED CONTROLLED TRIAL
Ta-Chih Liu, Shen-Fung Lin, Chao-Sung Chang, Wen-Chi Yang, Tyen-Po Chen
Despite efforts to improve iron supplements for iron deficiency anemia, there is no consensus on products that balance efficacy, safety and tolerability, and cost. Ferrous products are effective, but they are associated with more gastrointestinal side effects than ferric products. Ferric products tend to have lower absorption. We present results from a 12-week study that randomized 72 people with uncomplicated iron deficiency anemia to receive a ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin) or a ferric iron polysaccharide complex (Niferex, ferro-glycine sulfate) plus ascorbic acid...
December 2004: International Journal of Hematology
#3
JOURNAL ARTICLE
F PICCININI
No abstract text is available yet for this article.
April 1961: Archivio Italiano di Scienze Farmacologiche
#4
JOURNAL ARTICLE
E BEUTLER, S E LARSH
No abstract text is available yet for this article.
September 13, 1962: New England Journal of Medicine
1